Detalhe da pesquisa
1.
t(9;12)(q22;p13) ETV6::SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia.
Br J Haematol
; 200(5): 665-668, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36385372
2.
A monocentric retrospective study of 138 therapy-related myeloid neoplasms.
Ann Hematol
; 97(12): 2319-2324, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30203335
3.
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Haematologica
; 100(7): 893-7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25934766
4.
Next generation sequencing in therapy-related myeloid neoplasms compared to de novo myeloid neoplasms.
Acta Clin Belg
; 77(3): 658-663, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34197279
5.
The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).
Haematologica
; 96(6): 922-6, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21330321
6.
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.
Ann Hematol
; 94(11): 1927-8, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26202607
7.
Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1.
Br J Haematol
; 165(5): 734-7, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24611479
8.
Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.
Blood
; 120(7): 1529-31, 2012 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-22899477
9.
Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen.
Haematologica
; 94(10): 1440-4, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19794087
10.
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.
Cancers (Basel)
; 11(12)2019 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31888289
11.
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
Haematologica
; 92(1): 27-34, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17229632
12.
Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients.
Acta Clin Belg
; 72(2): 123-129, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28262030
13.
FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia.
Hemasphere
; 3(2): e182, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31723821
14.
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
Exp Hematol
; 42(4): 282-293.e4, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24407160
15.
TV6 and PDGFRB: a license to fuse.
Haematologica
; 92(2): 145-7, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17296561
16.
Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
Expert Rev Anticancer Ther
; 9(9): 1295-304, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19761433
17.
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Blood
; 108(4): 1374-6, 2006 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16645167